	US 12,441,990 B2
	Host cell including expression vector for encoding catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants
Shengjiang Liu, Hayward, CA (US)
Assigned to AVIRMAX, INC., Hayward, CA (US)
Filed by AVIRMAX, INC., Hayward, CA (US)
Filed on Jan. 5, 2024, as Appl. No. 18/405,043.
Application 18/405,043 is a continuation of application No. 17/823,066, filed on Aug. 29, 2022, granted, now 11,898,178.
Application 17/823,066 is a continuation of application No. 17/368,755, filed on Jul. 6, 2021, granted, now 11,453,869, issued on Sep. 27, 2022.
Claims priority of provisional application 63/093,788, filed on Oct. 19, 2020.
Claims priority of provisional application 63/048,645, filed on Jul. 6, 2020.
Prior Publication US 2024/0218343 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/48 (2006.01); C12N 15/86 (2006.01)

CPC C12N 9/485 (2013.01) [C12N 15/86 (2013.01); C12Y 304/17023 (2013.01)]

2 Claims

1. A host cell comprising an expression vector, the vector comprising a polynucleotide selected from the group consisting of SEQ ID NOs: 64, 66, 67, 68, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80 and 81.